Recently, the National Development and Reform Commission issued an industry research report. The report pointed out that the economic benefits of China's pharmaceutical industry will rise sharply this year, but the pharmaceutical industry will continue to face rising costs in the second half of the year, and the impact of factors such as the rising cost of upstream raw materials on the continued development of the industry deserves attention. At the same time, the report optimistically predicted that the growth of the economic benefits of the pharmaceutical industry in 2007 will hopefully go beyond the downturn in 2006, and the increase will rebound to more than 30%.
According to statistics, in the first half of this year, China's pharmaceutical industry accumulated a total industrial output value of 310 billion yuan, a year-on-year increase of 22.5%. Among them, the growth rate of the sub-industries such as the processing of traditional Chinese medicine decoction pieces, sanitary materials and medical supplies, chemical raw material drugs, bio-biochemical drugs, and medical instrument equipment and apparatus is higher than the average level of the industry. At the same time, the average production and sales rate of the pharmaceutical industry was 93.97%, and the total sales value of the industry was 291.3 billion yuan, a year-on-year increase of 22.7%. According to statistics, from January to May, the entire industry realized a profit of 19.8 billion yuan, a year-on-year increase of 36.1%, which is the highest level since the "10th Five-Year Plan." However, China's pharmaceutical industry is still facing a series of issues such as the continued decline in drug prices and rising raw material prices. According to statistics, in the first five months of this year, there were 1,384 loss-making enterprises in the pharmaceutical industry, with an industry loss of 24%, and a cumulative loss of 1.81 billion yuan, a year-on-year increase of 1.1%.
At the same time, the growth rate of exports of pharmaceutical products slowed down, and the prices of drugs continued to decline. According to statistics, from January to June, the export value of medical products completed was 37.9 billion yuan, an increase of 20.6% year-on-year, and the growth rate decreased by 5.17 percentage points.
The rise in prices of APIs has made the pharmaceutical industry worse. It is understood that in March of this year, the State Environmental Protection Administration announced a total of 6066 industrial pollution sources in key monitoring companies, pharmaceutical companies accounted for 117, mainly in the fermentation of raw material pharmaceutical companies. Some companies have stopped production due to environmental issues, resulting in tighter market supply. This year, prices of penicillin industrial salt, vitamins, and other food-based fermentation products have risen to varying degrees.
According to statistics, in the first half of this year, China's pharmaceutical industry accumulated a total industrial output value of 310 billion yuan, a year-on-year increase of 22.5%. Among them, the growth rate of the sub-industries such as the processing of traditional Chinese medicine decoction pieces, sanitary materials and medical supplies, chemical raw material drugs, bio-biochemical drugs, and medical instrument equipment and apparatus is higher than the average level of the industry. At the same time, the average production and sales rate of the pharmaceutical industry was 93.97%, and the total sales value of the industry was 291.3 billion yuan, a year-on-year increase of 22.7%. According to statistics, from January to May, the entire industry realized a profit of 19.8 billion yuan, a year-on-year increase of 36.1%, which is the highest level since the "10th Five-Year Plan." However, China's pharmaceutical industry is still facing a series of issues such as the continued decline in drug prices and rising raw material prices. According to statistics, in the first five months of this year, there were 1,384 loss-making enterprises in the pharmaceutical industry, with an industry loss of 24%, and a cumulative loss of 1.81 billion yuan, a year-on-year increase of 1.1%.
At the same time, the growth rate of exports of pharmaceutical products slowed down, and the prices of drugs continued to decline. According to statistics, from January to June, the export value of medical products completed was 37.9 billion yuan, an increase of 20.6% year-on-year, and the growth rate decreased by 5.17 percentage points.
The rise in prices of APIs has made the pharmaceutical industry worse. It is understood that in March of this year, the State Environmental Protection Administration announced a total of 6066 industrial pollution sources in key monitoring companies, pharmaceutical companies accounted for 117, mainly in the fermentation of raw material pharmaceutical companies. Some companies have stopped production due to environmental issues, resulting in tighter market supply. This year, prices of penicillin industrial salt, vitamins, and other food-based fermentation products have risen to varying degrees.
ZHEJIANG FULE MINING MACHINERY CO., LTD , https://www.flmachines.com